Supplementary Appendix from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

This is a Experimental Study study.

Key Points

Anti-CD39 mAb, alone or combined with durvalumab, aims to improve outcomes in advanced solid tumors.
The analysis reveals potential synergistic effects between anti-CD39 mAb and durvalumab in treatment regimens.
Observational analysis evaluates treatment responses among patients with advanced solid tumors receiving these therapies.
The findings suggest further studies are needed to confirm the efficacy and safety of these treatment combinations.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

This analysis explores anti-cd39 mab's efficacy alone or with durvalumab in advanced solid tumors, indicating potential treatment benefits.

Supplementary Appendix and Study Representativeness Figure

No takes yet. Share an insight, caveat, or question.

Powderly et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share